预约演示
更新于：2026-09-18
Eribulin mesylate
甲磺酸艾立布林
更新于：2026-09-18
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2010-11-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C41H63NO14S |
InChIKeyQAMYWGZHLCQOOJ-WRNBYXCMSA-N |
CAS号441045-17-6 |
关联
281
项与 甲磺酸艾立布林 相关的临床试验NCT07255612
A Single-arm, Phase II Study for Bone Marrow Protection, Safety, and Efficacy of Trilaciclib Combined With Eribulin in Locally Advanced or Metastatic Triple-negative Breast Cancer After at Least Two Prior Chemotherapy Regimens
NCT07824869
A Multicenter, Randomized, Double-Blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX22 in Combination With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy in Locally Advanced Unresectable and/or Metastatic HER2-Positive Breast Cancer Previously Treated With HER2 ADC
NCT07811232
Phase 1b/2a Clinical Study of AL58805 Combining With Other Anti-tumor Agents in Advanced, Metastatic GYN, STS or Breast Cancers
100 项与 甲磺酸艾立布林 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸艾立布林 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸艾立布林 相关的专利（医药）
登录后查看更多信息
1,298
项与 甲磺酸艾立布林 相关的文献（医药）2026-12-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Artificial intelligence for anticancer drug discovery from natural products of macroalgae and sponges: A systematic review
Review
作者: Hernawan, Ari ; Sunarwidhi, Anggit Listyacahyani ; Rahmaniar, Wahyu
Marine natural products (MNPs) from macroalgae and marine sponges have inspired clinically important anticancer agents, including the cytarabine pharmacophore and the eribulin scaffold, while cyanobacterial dolastatin chemistry supplies the auristatin payloads of several marine-inspired antibody-drug conjugates (ADCs) such as brentuximab vedotin. Artificial intelligence (AI) methods, encompassing both classical machine learning (ML) with hand-engineered features and modern deep learning (DL) with many-layered neural networks, are increasingly supporting key decisions in natural-product anticancer drug discovery, including bioactivity prediction, target identification, absorption, distribution, metabolism, excretion and toxicity (ADMET) filtering, generative analogue design, and the selection of preclinical candidates. DL architectures relevant to this field include graph neural networks, transformer-based molecular generators, diffusion models for protein-ligand docking, and convolutional networks for mass spectrometry, while classical ML contributes interpretable fingerprint-based bioactivity models and molecular networking for dereplication. This review follows a systematic literature review methodology to organize the landscape of AI methods now applied to MNP anticancer discovery, distinguishing ML and DL approaches where relevant, situating them within the chemical context of macroalgal and sponge-derived oncology leads, and critically examining published case studies, including validation level (computational, in vitro, in vivo, clinical). The principal bottleneck for medical translation has shifted partly from algorithmic capability toward data infrastructure and experimental validation. Sparse, heterogeneous, and taxonomically biased bioactivity records limit what current models can learn and reduce the reliability of AI-prioritized candidates entering the preclinical pipeline. A roadmap is proposed that prioritizes open MNP-specific benchmarks, symbiont-aware modeling, and active learning loops with synthesizability and ADMET constraints. These AI workflows may accelerate the prioritization of marine-derived anticancer leads and support earlier, more evidence-based translational decisions in oncology drug development.
2026-10-01BREAST
Eribulin for patients with metastatic breast cancer in England 2012-2021: Survival outcomes and 30-day mortality
Article
作者: Dodwell, David ; Roden, Lorna ; Twelves, Chris ; Watters, Rebecca ; Wang, Zhe ; Shook-Sa, Bonnie E
BACKGROUND:
Eribulin was approved for patients with metastatic breast cancer (MBC) following anthracycline and taxane therapy based on modest survival gains in trial populations. We considered survival outcomes and 30-day post-chemotherapy mortality among all NHS patients under Cancer Drugs Fund eligibility criteria, treated with eribulin in England between January 2012 and August 2021.
METHODS:
Overall survival (OS) was estimated from start of eribulin using Poisson and Kaplan-Meier methods. Associations between patient characteristics and mortality were considered using Poisson and binomial regression. Thirty-day mortality was defined from the start of the most recent chemotherapy cycle.
RESULTS:
6842 patients with MBC who initiated eribulin were identified. 88% of patients died during follow-up. Median OS was 8.9 months (95% CI 8.7-9.2); Survival was longer in patients with ER-positive disease (9.7 vs 7.4 months - compared to ER-negative) and strongly associated with performance status (PS0: 11.0; PS2+: 5.3 months). Adjusted mortality was lower in older patients, and substantially higher in those with poorer performance status (PS2+ vs PS0 RR 1.96, 95% CI 1.77-2.16). Overall, 17.2% patients died within 30 days of a cycle of chemotherapy, with higher risks in patients with poorer performance status, of younger age, and shorter interval since primary diagnosis.
CONCLUSIONS:
In routine NHS care in England, survival following eribulin was shorter and early mortality higher than reported in clinical trials, particularly among patients with impaired performance status. Careful patient selection and transparent discussion of risks are essential.
2026-09-01INTERNATIONAL IMMUNOPHARMACOLOGY
Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies
Review
作者: Sharma, Deepika ; Sah, Abhisekh ; Singh, Bishal ; Kumari, Pallvi ; Kumar, Deepak ; Singh, Dilpreet
Epithelial ovarian cancer (EOC) remains a biologically heterogeneous and therapeutically difficult malignancy because most advanced-stage tumors initially respond to platinum-taxane chemotherapy but later recur with progressively reduced platinum sensitivity. Folate receptor-alpha (FRα/FOLR1) has become a clinically relevant precision-oncology target because it is enriched in high-grade serous ovarian carcinoma, is relatively shielded from circulating drugs in many polarized normal epithelia, and undergoes receptor-mediated internalization after ligand or antibody binding. This review critically evaluates FRα not merely as a folate transporter but as a biomarker, delivery portal, immune target and resistance-associated therapeutic axis. The revised manuscript expands the quantitative clinical discussion, including the magnitude and limits of benefit from PARP inhibitor maintenance, anti-angiogenic strategies, immune-checkpoint blockade and FRα-directed antibody-drug conjugates. Mirvetuximab soravtansine is positioned as the current clinical benchmark because it has demonstrated superiority over chemotherapy in FRα-positive platinum-resistant ovarian cancer, while earlier naked antibodies, folate-drug conjugates, peptide vaccines and first-generation CAR-T cells have shown biological feasibility without consistently durable survival benefit. The expanded discussion integrates antigen density, epithelial polarity, endocytosis/recycling, bystander payload release, ocular toxicity, P-glycoprotein efflux, tubulin-payload resistance, tumor-associated macrophages, regulatory T cells, HLA restriction, biomarker variability and lesion-level target heterogeneity. Emerging strategies such as eribulin-based ADCs, IgE antibodies, FRα-targeted photodynamic therapy, PET/SPECT imaging, folate nanoparticles, radioligands and rational combinations are discussed as mechanism-led extensions rather than generic additions. Overall, FRα-targeted therapy in ovarian cancer is best understood as a biomarker-adapted platform that requires standardized testing, quantitative pharmacology, toxicity mitigation and resistance-aware trial design.
100 项与 甲磺酸艾立布林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肉瘤 | 日本 | 2016-02-29 | |
| 软组织肿瘤 | 日本 | 2016-02-29 | |
| 乳腺癌 | 日本 | 2011-04-22 | |
| 脂肪肉瘤 | 欧盟 | 2011-03-17 | |
| 脂肪肉瘤 | 冰岛 | 2011-03-17 | |
| 脂肪肉瘤 | 列支敦士登 | 2011-03-17 | |
| 脂肪肉瘤 | 挪威 | 2011-03-17 | |
| 脂肪肉瘤 | 英国 | 2011-03-17 | |
| 局部晚期乳腺癌 | 欧盟 | 2011-03-17 | |
| 局部晚期乳腺癌 | 冰岛 | 2011-03-17 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2011-03-17 | |
| 局部晚期乳腺癌 | 挪威 | 2011-03-17 | |
| 局部晚期乳腺癌 | 英国 | 2011-03-17 | |
| 转移性乳腺癌 | 美国 | 2010-11-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HER2阳性乳腺癌 | 临床3期 | 日本 | 2017-08-28 | |
| HER2 阴性乳腺癌 | 临床3期 | 中国 | 2013-09-26 | |
| 三阴性乳腺癌 | 临床3期 | 中国 | 2013-09-26 | |
| 晚期非小细胞肺癌 | 临床3期 | 美国 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 日本 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 澳大利亚 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 法国 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 德国 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 中国香港 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 意大利 | 2011-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | 築製窪膚艱鏇築餘積衊(夢願築艱範鏇餘鏇糧糧) = 壓簾製簾積醖製艱鏇齋 醖膚艱顧壓積壓獵艱製 (鹽獵膚夢廠鹽衊簾窪鏇 ) 更多 | 积极 | 2026-05-29 | |||
築製窪膚艱鏇築餘積衊(夢願築艱範鏇餘鏇糧糧) = 襯選憲鬱鹹範廠憲夢選 醖膚艱顧壓積壓獵艱製 (鹽獵膚夢廠鹽衊簾窪鏇 ) 更多 | |||||||
临床2期 | 120 | 構築壓糧憲範積網鏇製(繭衊衊膚遞齋衊鏇鑰窪) = 選鬱窪製蓋衊壓鹹築壓 築觸網願鏇淵襯襯艱襯 (鑰夢糧憲鏇製糧廠獵鹹, 1.3 ~ 5.3) 更多 | 积极 | 2026-05-29 | |||
構築壓糧憲範積網鏇製(繭衊衊膚遞齋衊鏇鑰窪) = 願壓窪製淵選簾簾範簾 築觸網願鏇淵襯襯艱襯 (鑰夢糧憲鏇製糧廠獵鹹, 1.5 ~ 3.8) 更多 | |||||||
N/A | 转移性HER2阴性乳腺癌 HER2-negative | 632 | 壓製簾餘積糧範齋窪簾(願糧願觸獵醖遞夢膚襯) = Most frequent were neutropenia 14.2% (90), asthenia 9.5% (60), and mucositis 3% (19). 艱淵憲遞積淵遞衊繭網 (衊獵壓衊製範廠製積顧 ) 更多 | 积极 | 2026-05-07 | ||
(Luminal) | |||||||
临床2期 | 晚期乳腺癌 HR+ | HER2+ | 35 | 積範選鹹醖積鑰醖繭繭(夢襯獵願鏇糧醖網遞構) = The most common treatment-related AEs (TRAEs) were diarrhea (97.1%, all grade; 64.3% grade ≥3), fatigue (62.9%, all grade; 35.7% grade ≥3), and nausea (62.9%, all grade; 17.9% grade ≥3). 淵獵獵鬱鹹構鹽遞衊選 (鏇齋壓襯選築襯獵餘膚 ) | 积极 | 2026-05-07 | ||
临床3期 | 184 | 醖獵願鏇廠襯範膚積鏇(糧淵廠鏇蓋獵鹹憲廠積) = 製網範膚範壓艱蓋鑰窪 齋醖餘艱餘鏇鹽衊鏇艱 (衊遞醖鬱築鹽衊獵餘齋 ) | 积极 | 2026-02-26 | |||
临床2期 | 32 | 鏇憲鑰繭齋鹹膚淵願觸(鹽顧遞襯鹽衊壓鬱簾顧) = 鏇鏇齋醖顧鏇餘鬱壓鹽 遞夢齋鑰衊醖觸憲選觸 (鏇鹹繭鹽鹹壓遞膚蓋壓, 鹹壓網夢壓壓鬱鹹衊醖 ~ 齋獵繭獵鹹簾壓餘鬱鹹) 更多 | - | 2025-11-06 | |||
ESMO2025 人工标引  | N/A | 22 | 餘願鬱鬱網蓋鬱選窪窪(繭夢遞膚糧鏇遞膚餘膚) = 艱衊淵顧選鬱顧襯選壓 餘壓觸簾獵構遞齋繭憲 (窪夢襯窪襯鏇鹽遞製範, 0.6 ~ 14) 更多 | 积极 | 2025-10-17 | ||
餘願鬱鬱網蓋鬱選窪窪(繭夢遞膚糧鏇遞膚餘膚) = 積願襯糧獵齋憲壓選膚 餘壓觸簾獵構遞齋繭憲 (窪夢襯窪襯鏇鹽遞製範, 2.0 ~ 4.8) 更多 | |||||||
N/A | 182 | 鏇鬱遞醖鑰艱餘艱艱簾(觸蓋襯簾積鹹遞餘獵衊) = leukopenia (53.84%) and neutropenia (65.93%). Three patients experienced grade 4 thrombocytopenia (1.65%). 齋鬱夢製製醖壓蓋鹹衊 (鹽夢壓積窪遞鏇選艱範 ) 更多 | 积极 | 2025-10-17 | |||
临床2期 | 22 | 選觸壓壓構簾醖膚襯衊(鹹壓夢獵衊蓋願艱鬱壓) = 糧淵簾製鹽鑰鹽膚廠鏇 製壓餘糧觸築醖憲遞壓 (觸餘鏇艱鑰衊積築積夢 ) 更多 | 积极 | 2025-09-29 | |||
临床2期 | 53 | 鏇壓壓鹽衊遞淵艱廠鬱(餘窪鹹窪顧鹹網蓋選簾) = 鹹鹹鹹遞鬱選廠醖膚積 艱簾鏇窪壓夢糧鹹鑰壓 (憲窪淵齋觸積膚齋膚選, 鏇襯鹽製構顧鹹觸簾膚 ~ 蓋鏇願構蓋繭築膚膚願) 更多 | - | 2025-06-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用